Cardiosense builds a wearable sensor and AI platform for cardiac monitoring, combining seismocardiogram, photoplethysmogram, and electrocardiogram signals into clinical algorithms that flag worsening heart failure before hospitalization. The company has FDA De Novo Classification for its cardiac-monitoring technology and works with health-system and payer partners on early-warning heart failure programs.
1
Round
1
Industry
5
Tags
Aug 24, 2026
Latest raise
Funding activity · 1 round
Aug 24, 2026
$26.1M
Series B
Cardiosense, a company developing a wearable sensor and AI platform for cardiac monitoring, has raised $26.1 million in a Series B funding round, according to a filing dated August 24, 2026. The round did not list any participating investors.
The company's platform combines seismocardiogram, photoplethysmogram, and electrocardiogram signals into clinical algorithms that flag worsening heart failure before hospitalization. Cardiosense has received FDA De Novo Classification for its cardiac-monitoring technology and works with health-system and payer partners on early-warning heart failure programs.
The new funding will support the company's continued development and commercialization efforts, though specific plans were not disclosed.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
